An undeniable advantage of such panels as the combinations of CEA, IL-6, SAA1, MMP-9, and lactate, IL-6, glucose, and LDH, or CEA, IL-6, and LDH is the ability of its detection in patients’ blood and use in a large group of NSCLC patients whose tumor tissue is not easily accessible, particularly in peripherally situated adenocarcinomas. This evidence concerns the gene MMP9 and adenocarcinoma.